Dr. Litton on a Study of Neoadjuvant Talazoparib for Patients With BRCA-Mutated TNBC
December 6th 2018Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses a neoadjuvant study of talazoparib (Talzenna) for patients with BRCA1/2 mutated triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.
Read More